SCHEMBL6324432

SCHEMBL6324432

Nc1onc(-c2ccc(Br)s2)c1C(=O)NCCC(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.48
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RXFP1 Q9HBX9 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CNR1 P21554 3/20 0.39
CNR2 P34972 2/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6616829 0.91 RXFP1 (0.45) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL6323623 0.89 EPHX2 (0.49) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL6317382 0.88 CA1 (0.52) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL6320941 0.87 EPHX2 (0.47) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL6315554 0.86 RXFP1 (0.49) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL6320986 0.85 MEN1 (0.47) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL6321492 0.84 L3MBTL1 (0.53) ALDH1A1MAPTHPGDNPSR1SMN1; SMN2
SCHEMBL6324462 0.83 GAA (0.46) ALDH1A1MAPTHPGDNPSR1RXFP1
SCHEMBL6318741 0.83 L3MBTL1 (0.49) ALDH1A1MAPTHPGDNPSR1RXFP1
SCHEMBL6317494 0.83 RAB9A (0.43) ALDH1A1MAPTHPGDNPSR1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 EPHX2 4156/4885ALDH1A1 4444/4885MAPT 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.